Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined
with Vinorelbine as third-line and posterior line treatment in patients with NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University